Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

NCT ID: NCT02674269

Last Updated: 2017-06-16

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2016-10-31

Brief Summary

The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.

Detailed Description

Overactive bladder (OAB) is a syndrome, defined by the International Continence Society (ICS), as the presence of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of a urinary tract infection (UTI) or other obvious pathology." This study will evaluate a new of mode of treatment, with intravesical bladder instillation with Botox® mixed with TC-3 that may bypass the drawbacks of the current bladder injection treatment mode in OAB patients. Additionally it will provide preliminary safety and efficacy data that may serve as a basis for a larger study exploring safety and efficacy aspects of this new mode of treatment.

50 patients will be randomized in a horse race fashion in a ~2:2:1 ratio. The patients will be screened for up to 3 weeks prior to treatment.

The patients will be requested to stop their OAB medications 7 days prior to treatment visit. 20 patients will receive one instillation of 300U of BotuGel (60ml), 20 patients will receive one instillation of 400U of BotuGel (60ml) and 10 patients will receive one instillation of 60 ml RTGel-TC-3 Gel (Placebo), all patients will be followed up for safety and efficacy endpoints until 6 weeks post instillation.

Conditions

Overactive Bladder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

300 IU of BotuGelTM (60ml)

One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel

Group Type: EXPERIMENTAL

300 IU of BotuGelTM (60ml)

Intervention Type: DRUG

One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel

400 IU of BotuGelTM (60ml)

One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel

Group Type: EXPERIMENTAL

400 IU of BotuGelTM (60ml)

Intervention Type: DRUG

One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel

TC-3 Gel

One intravesical instillation of 60 ml TC-3 gel

Group Type: PLACEBO_COMPARATOR

TC-3 Gel

Intervention Type: DEVICE

Intravesical instillation of 60 ml TC-3 gel

Interventions

300 IU of BotuGelTM (60ml)

One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel

Intervention Type: DRUG

400 IU of BotuGelTM (60ml)

One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel

Intervention Type: DRUG

TC-3 Gel

Intravesical instillation of 60 ml TC-3 gel

Intervention Type: DEVICE

Other Intervention Names

BotuGelTM 300; BotuGelTM 400

Eligibility Criteria

Inclusion Criteria

• Female patient 18 to 75 years old diagnosed with idiopathic OAB.
• Patient has symptoms of OAB for ≥ 3 months prior to screening.
• Patient is a non-responder to pharmacologic therapy or has intolerable side effects or is not compliant to the treatment.
• On screening three-day voiding diary- Patient has a frequency of at least 8 micturitions per 24 hours & Total of ≥3 urgency urinary incontinence (UUI) episodes.
• Patient is willing and able to initiate self catheterization post-treatment, if required.
• Patients has PVR ≤100 ml. Patient with a single PVR of >100 ml and followed by two consecutive PVR measurements of <100 ml may be included in the study).

Exclusion Criteria

• Patient currently uses CIC or indwelling catheter to manage their urinary incontinence
• Patient who has clinically significant Bladder Outlet Obstruction (BOO).
• Patient with active urinary tract infection.
• OAB due to any known neurological reason.
• Patient with 24-hour total urine volume voided greater than 3,000 ml as measured at screening visit.
• Predominance of stress incontinence in the opinion of the investigator, determined by patient history.
• Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening.
• Patient with prior botulinum toxin therapy of any serotype within 12 weeks for any indication.
• Patient with prior use of Botulinum toxin therapy of any serotype for any urological condition.
• Patient with previous pelvic radiation therapy.
• Patient had been treated for two or more UTIs within last 6 months or use of prophylactic antibiotics to prevent chronic UTIs.
• ANY condition identified which may cause overactive bladder symptoms

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

UroGen Pharma Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ifat Klein, PhD

Role: STUDY_DIRECTOR

iklein@urogen.com

Locations

Rambam Health Care Campus

Haifa, , Israel

Meir Medical Center

Kfar Saba, , Israel

Countries

Israel

Other Identifiers

TC-OAB-03-P

Identifier Type: -

Identifier Source: org_study_id